CN Bio
Generated by Meeveem AI
"Predictive human organ models transforming drug discovery and reducing animal testing"
Cambridge
•51 - 250 Employees
•Medical Devices
About CN Bio
CN Bio develops organ-on-a-chip technology that recreates three-dimensional human organs and tissues in the laboratory. The PhysioMimix platform generates human-relevant data for drug efficacy, safety, and metabolism studies, addressing the gap between animal models and human clinical outcomes. This enables pharmaceutical companies to make better informed decisions earlier in drug development. The platform serves researchers and pharmaceutical companies seeking more accurate preclinical testing. By providing predictive human biology models, CN Bio helps reduce development timelines, lower costs, and decrease reliance on animal experimentation. Sixteen of the top twenty pharmaceutical companies use PhysioMimix systems.
58
Team Members
2014
Founded
Medical Devices
Sector
Hybrid
Work Environment
Our Vision
A future where life-saving drugs reach patients faster and more affordably through predictive human biology models, eliminating unnecessary animal testing and accelerating medical breakthroughs that improve human health worldwide
Our Mission
Enables researchers to recreate three-dimensional human organs and tissues in the laboratory to better understand human physiology, disease, and the effectiveness of new drugs